vs
Side-by-side financial comparison of Kennedy-Wilson Holdings, Inc. (KW) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($196.9M vs $120.6M, roughly 1.6× Kennedy-Wilson Holdings, Inc.). On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.1% vs -11.0%). Pacira BioSciences, Inc. produced more free cash flow last quarter ($43.5M vs $-55.2M). Over the past eight quarters, Pacira BioSciences, Inc.'s revenue compounded faster (8.5% CAGR vs -6.0%).
Kennedy Wilson is a real estate investment company headquartered in Beverly Hills, California, United States.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
KW vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $120.6M | $196.9M |
| Net Profit | $58.0M | — |
| Gross Margin | — | 79.5% |
| Operating Margin | 57.3% | 1.2% |
| Net Margin | 48.1% | — |
| Revenue YoY | -11.0% | 5.1% |
| Net Profit YoY | 32.7% | — |
| EPS (diluted) | $0.22 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $120.6M | $196.9M | ||
| Q3 25 | $116.4M | $179.5M | ||
| Q2 25 | $135.7M | $181.1M | ||
| Q1 25 | $128.3M | $168.9M | ||
| Q4 24 | $135.5M | $187.3M | ||
| Q3 24 | $127.5M | $168.6M | ||
| Q2 24 | $132.0M | $178.0M | ||
| Q1 24 | $136.4M | $167.1M |
| Q4 25 | $58.0M | — | ||
| Q3 25 | $-10.2M | $5.4M | ||
| Q2 25 | $5.6M | $-4.8M | ||
| Q1 25 | $-29.6M | $4.8M | ||
| Q4 24 | $43.7M | — | ||
| Q3 24 | $-66.8M | $-143.5M | ||
| Q2 24 | $-48.3M | $18.9M | ||
| Q1 24 | $37.7M | $9.0M |
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 76.9% | ||
| Q2 24 | — | 75.1% | ||
| Q1 24 | — | 71.6% |
| Q4 25 | 57.3% | 1.2% | ||
| Q3 25 | -6.2% | 3.5% | ||
| Q2 25 | 7.4% | 4.7% | ||
| Q1 25 | -26.9% | 1.2% | ||
| Q4 24 | 36.7% | 13.2% | ||
| Q3 24 | -60.8% | -82.8% | ||
| Q2 24 | -45.5% | 15.9% | ||
| Q1 24 | 47.2% | 7.9% |
| Q4 25 | 48.1% | — | ||
| Q3 25 | -8.8% | 3.0% | ||
| Q2 25 | 4.1% | -2.7% | ||
| Q1 25 | -23.1% | 2.8% | ||
| Q4 24 | 32.3% | — | ||
| Q3 24 | -52.4% | -85.1% | ||
| Q2 24 | -36.6% | 10.6% | ||
| Q1 24 | 27.6% | 5.4% |
| Q4 25 | $0.22 | $0.05 | ||
| Q3 25 | $-0.15 | $0.12 | ||
| Q2 25 | $-0.05 | $-0.11 | ||
| Q1 25 | $-0.30 | $0.10 | ||
| Q4 24 | $0.24 | $0.38 | ||
| Q3 24 | $-0.56 | $-3.11 | ||
| Q2 24 | $-0.43 | $0.39 | ||
| Q1 24 | $0.19 | $0.19 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $184.5M | $238.4M |
| Total DebtLower is stronger | — | $372.2M |
| Stockholders' EquityBook value | $1.5B | $693.1M |
| Total Assets | $6.6B | $1.3B |
| Debt / EquityLower = less leverage | — | 0.54× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $184.5M | $238.4M | ||
| Q3 25 | $382.6M | $246.3M | ||
| Q2 25 | $309.1M | $445.9M | ||
| Q1 25 | $356.6M | $493.6M | ||
| Q4 24 | $217.5M | $484.6M | ||
| Q3 24 | $367.1M | $453.8M | ||
| Q2 24 | $366.5M | $404.2M | ||
| Q1 24 | $541.9M | $325.9M |
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $1.5B | $693.1M | ||
| Q3 25 | $1.5B | $727.2M | ||
| Q2 25 | $1.6B | $757.8M | ||
| Q1 25 | $1.6B | $798.5M | ||
| Q4 24 | $1.6B | $778.3M | ||
| Q3 24 | $1.6B | $749.6M | ||
| Q2 24 | $1.7B | $879.3M | ||
| Q1 24 | $1.7B | $892.2M |
| Q4 25 | $6.6B | $1.3B | ||
| Q3 25 | $6.7B | $1.3B | ||
| Q2 25 | $6.8B | $1.5B | ||
| Q1 25 | $7.2B | $1.6B | ||
| Q4 24 | $7.0B | $1.6B | ||
| Q3 24 | $7.4B | $1.5B | ||
| Q2 24 | $7.5B | $1.6B | ||
| Q1 24 | $7.7B | $1.6B |
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $11.4M | $43.7M |
| Free Cash FlowOCF − Capex | $-55.2M | $43.5M |
| FCF MarginFCF / Revenue | -45.8% | 22.1% |
| Capex IntensityCapex / Revenue | 55.2% | 0.1% |
| Cash ConversionOCF / Net Profit | 0.20× | — |
| TTM Free Cash FlowTrailing 4 quarters | $-103.5M | $136.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $11.4M | $43.7M | ||
| Q3 25 | $-7.6M | $60.8M | ||
| Q2 25 | $42.0M | $12.0M | ||
| Q1 25 | $-51.9M | $35.5M | ||
| Q4 24 | $55.1M | $33.1M | ||
| Q3 24 | $-5.6M | $53.9M | ||
| Q2 24 | $36.7M | $53.2M | ||
| Q1 24 | $-5.6M | $49.1M |
| Q4 25 | $-55.2M | $43.5M | ||
| Q3 25 | $-18.0M | $57.0M | ||
| Q2 25 | $29.4M | $9.3M | ||
| Q1 25 | $-59.7M | $26.9M | ||
| Q4 24 | $-76.5M | $31.0M | ||
| Q3 24 | $-27.7M | $49.8M | ||
| Q2 24 | $-500.0K | $51.6M | ||
| Q1 24 | $-57.1M | $46.3M |
| Q4 25 | -45.8% | 22.1% | ||
| Q3 25 | -15.5% | 31.7% | ||
| Q2 25 | 21.7% | 5.1% | ||
| Q1 25 | -46.5% | 15.9% | ||
| Q4 24 | -56.5% | 16.6% | ||
| Q3 24 | -21.7% | 29.6% | ||
| Q2 24 | -0.4% | 29.0% | ||
| Q1 24 | -41.9% | 27.7% |
| Q4 25 | 55.2% | 0.1% | ||
| Q3 25 | 8.9% | 2.2% | ||
| Q2 25 | 9.3% | 1.5% | ||
| Q1 25 | 6.1% | 5.1% | ||
| Q4 24 | 97.1% | 1.1% | ||
| Q3 24 | 17.3% | 2.4% | ||
| Q2 24 | 28.2% | 0.9% | ||
| Q1 24 | 37.8% | 1.7% |
| Q4 25 | 0.20× | — | ||
| Q3 25 | — | 11.20× | ||
| Q2 25 | 7.50× | — | ||
| Q1 25 | — | 7.37× | ||
| Q4 24 | 1.26× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 2.82× | ||
| Q1 24 | -0.15× | 5.47× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
KW
| Consolidated Portfolio Segment | $84.9M | 70% |
| Investment Management Fees | $30.4M | 25% |
| Real Estate | $5.1M | 4% |
PCRX
| EXPAREL | $155.8M | 79% |
| ZILRETTA | $33.0M | 17% |
| Iovera | $7.0M | 4% |
